5-氨基-(1,1'-联苯)-2-醇 | 19434-42-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-氨基-(1,1'-联苯)-2-醇
• 英文名称: 4-amino-6-phenylphenol
• 英文别名: 2-hydroxy-5-aminobiphenyl；5-amino<1,1'-biphenyl>-2-ol；amino-5 hydroxy-2 biphenyle；5-aminobiphenyl-2-ol；2-phenyl-p-aminophenol；5-Amino-biphenyl-2-ol；4-Amino-2-phenylphenol
• CAS: 19434-42-5
• 化学式: C₁₂H₁₁NO
• mdl: MFCD08361726
• 分子量: 185.225
• InChiKey: OUIITAOCYATDMY-UHFFFAOYSA-N

物化性质

• 熔点：
  201 °C
• 沸点：
  384.7±35.0 °C(Predicted)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-氨基-(1,1'-联苯)-2-醇 以 乙醇 、 水 、 甲苯 为溶剂， 反应 0.02h， 生成 N-[3-[(tert-butylamino)methyl]-4-hydroxy-5-phenylphenyl]acetamide
  参考文献：
  名称：

  Antimalarial drugs. 60. Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl][1,1'-biphenyl]-2-ols and N.omega.-oxides

  摘要：

  A series of 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides was prepared from the substituted 1-phenyl-2-propanones proceeding through the 5-nitro[1,1'-biphenyl]-2-ols, the corresponding amino, and acetamido derivatives to the N-[5-[(alkylamino)methyl]-6-hydroxy[1,1'-biphenyl]-3-yl]acetamides and final condensation with 4,7-dichloroquinoline or the N-oxide. In a quantitative structure-activity relationship study first run on 28 and later expanded to 40 substituted phenyl analogues and their N omega-oxides, increasing antimalarial potency vs. Plasmodium berghei in mice was found to be correlated with decreasing size (sigma MR) and electron donation (sigma sigma) of the phenyl ring substituents. A significant correlation with N omega-oxidation could not be demonstrated. Initial high activity against P. berghei infections in mice led to expanded studies that demonstrated in addition excellent activity against resistant strains of parasite, activity in primate models, and pharmacokinetic properties apparently allowing protection against infection for extended periods of time even after oral administration. Such properties encourage the clinical trial of a member of this class in man.

  DOI：

  10.1021/jm00156a009
• 作为产物：
  描述：

  邻苯基苯酚 在 palladium on activated charcoal 氢气 、 硝酸 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 20.0 ℃ 、275.79 kPa 条件下， 反应 4.0h， 生成 5-氨基-(1,1'-联苯)-2-醇
  参考文献：
  名称：

  Catalysis of the Photo-Fries Reaction:  Antibody-Mediated Stabilization of High Energy States

  摘要：

  A conformationally constrained hapten is presented that is capable of catalyzing the first antibody-mediated photo-Fries rearrangement. In this reaction, absorption of light energy by a diphenyl ether substrate results in homolytic C-O bond cleavage followed by recombination to yield biphenyl-derived products. The most proficient antibody studied converts 4-phenoxyaniline 15 into 2-hydroxy-5-aminobiphenyl 16 under high-intensity irradiation at a rate of 8.6 muM/min. These results support a recent hypothesis stating that immunization with conformationally constrained haptens provides higher titers for the acquisition of simple binding antibodies; however, in this case, conformational constraint does not ensure the development of more efficient catalysts. Using the obtained antibodies, the presence of products resulting from escape of free radicals from the solvent cage can be suppressed, altering the excited state energy surface such that free radicals are funneled into the formation of the desired biphenyl product. However, studies also show the inactivation of the antibodies as a result of photodecay of the biphenyl product. Using an isocyanate scavenging resin, the photodecay product could be removed and the inactivation of the antibody drastically reduced. Furthermore, despite the observed photodecay, turnover of the antibody was present; this represents the first case in which true turnover of a photochemical reaction using a catalytic antibody could be observed.

  DOI：

  10.1021/ja038016n
• 作为试剂：
  描述：

  4-氨基联苯 、 三氟乙酸酐 在 5-氨基-(1,1'-联苯)-2-醇 、 对氨基苯酚 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 2,2,2-trifluoro-4'-phenylacetanilide
  参考文献：
  名称：

  二苯醚的光化学重排机理。

  摘要：

  研究了二苯醚（1a）的光化学重排机理。在乙醇中照射1a，除苯酚（4，30％）和苯（5，25％）外，还产生了2-苯基苯酚（2，42％）和4-苯基苯酚（3，11％）作为重排产物。 。使用[（2）H（10）] 1a的交叉偶联实验表明2-和4-苯基苯酚的形成是一个分子内过程。在苯或甲苯中辐照1a可获得高收率的联苯。重排产物（2和3）的合并产率随着溶剂粘度的增加而增加，伴随着4的形成减少。所有结果都可以通过将1a激发成单线态和离解成自由基对中间体而合理化。涉及苯氧基和苯基基团。这些自由基的分子内重组产生重排产物，逸出然后从溶剂中抽出氢得到扩散产物。当1a的4位被给电子取代基（1b-e）占据时，芳氧基-苯基键裂解产生相应的重排产物胜于苯氧基-芳基键裂解。对于在位置4（1h，i）具有吸电子取代基的底物则相反。

  DOI：

  10.1021/jo9517196

文献信息

• Aryl aniline beta2 adrenergic receptor agonists
  申请人：——

  公开号：US20030229058A1

  公开（公告）日：2003-12-11

  The invention provides novel &bgr; 2 adrenergic receptor agonist compounds of formula (I): 1 wherein R 1 -R 13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with &bgr; 2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

  这项发明提供了式（I）的新型β2肾上腺素受体激动剂化合物： 其中R1-R13和w具有规范中描述的任何值。该发明还提供了这些化合物与其他治疗剂的组合，包含这些化合物和组合物的药物组合物，使用这些化合物治疗与β2肾上腺素受体活性相关的疾病的方法，以及用于制备这些化合物的有用的过程和中间体。
• Aryl diazonium nanomagnetic sulfate and potassium iodide: an iodination process
  作者：Eskandar Kolvari、Ali Amoozadeh、Nadiya Koukabi、Somayeh Otokesh、Mohsen Isari

  DOI：10.1016/j.tetlet.2014.02.073

  日期：2014.7

  procedure for the synthesis of iodoarenes is developed which involves the sequential diazotization–iodination of aromatic amines with sodium nitrite, nanomagnetic supported sulfonic acid, and potassium iodide under solvent-free conditions at room temperature.

  开发了一种简单高效的碘代芳烃合成方法，该方法涉及在无溶剂条件下于室温下用亚硝酸钠，纳米磁性负载的磺酸和碘化钾对芳族胺进行连续重氮化-碘化。
• [EN] DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS<br/>[FR] DÉRIVÉS DE TRIAZOLOPYRIDAZINES 6-SUBSTITUÉES EN TANT QU'AGONISTES DE REV-ERB
  申请人：GENFIT

  公开号：WO2013045519A1

  公开（公告）日：2013-04-04

  The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.

  本发明提供了新颖的激动Rev-Erb的6-取代[1,2,4]三唑并[4,3-b]吡啶嗪化合物。这些化合物以及包含它们的药物组合物是治疗任何激活Rev-Erb具有治疗效果的疾病的合适手段，例如在炎症和昼夜节律相关疾病或心脏代谢疾病中。
• Cyanate functional maleimides
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0291552A1

  公开（公告）日：1988-11-23

  Thermoset products are prepared by polymerizing (A) at least one thermosettable compound which contains both a maleimide group and a cyanate group such as 3-­(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)phenyl cyanate and optionally (B) at least one of (1) at least one aromatic polycyanate such as bisphenol A dicyanate; (2) at least one polymaleimide such as N,Nʹ-(methylenedi-p-­phenylene)bismaleimide; (3) at least one material having an average of more than one vicinal epoxide group per molecule such as a diglycidyl ether of bisphenol A; (4) at least one polymerizable ethylenically unsaturated material such as styrene; or (5) a mixture of any two or more of components 1-4 in any combination.

  热固性产品是通过聚合至少一种含有马来酰亚胺基团和氰酸基团的热固性化合物（如3-(2,5-二氢-2,5-二氧杂-1H-吡咯-1-基)苯基氰酸酯）（A）制备的，可选地还包括至少一种以下材料之一（B）：（1）至少一种芳香族聚氰酸酯（如双酚A二氰酸酯）；（2）至少一种聚马来酰亚胺（如N,N'-(亚甲基二-p-苯二亚甲基)双马来酰亚胺）；（3）至少一种每个分子平均含有多于一个邻二氧环氧基团的材料（如双酚A的二环氧基醚）；（4）至少一种可聚合的乙烯基不饱和材料（如苯乙烯）；或（5）组分1-4中任意两种或两种以上的混合物以任何组合形式。
• METHOD OF MANUFACTURING BIPYRIDINIUM COMPOUND AND SYNTHETIC INTERMEDIATE OF THE SAME, METHOD OF MANUFACTURING DYE COMPOUND, AND NOVEL BIPYRIDINIUM COMPOUND AND NOVEL DYE COMPOUND COMPRISING THE SAME
  申请人：Nii Kazumi

  公开号：US20090082570A1

  公开（公告）日：2009-03-26

  Provided is a method of manufacturing a bipyridinium compound denoted by general formula (A). In general formula (A), Ar 1 and Ar 2 each independently denote an optionally substituted (hetero)aryl group, R 3 and R 4 each independently denote a substituent that may form a ring with a pyridine ring to which the substituent substitutes, m3 and m4 each independently denote an integer ranging from 0 to 4, X denotes a halogen atom or RSO 3 , and R denotes an optionally substituted aryl group or alkyl group. The method can manufacture a 4,4′-bipyridinium compound under mild reaction conditions in an integrated manner without separation of intermediates.

  提供了一种制造双吡啶化合物的方法，其通用式为(A)。在通用式(A)中，Ar1和Ar2分别独立表示可选择取代的(杂)芳基团，R3和R4分别独立表示可与取代基形成环的基团，m3和m4分别独立表示范围从0到4的整数，X表示卤原子或RSO3，R表示可选择取代的芳基团或烷基团。该方法可以在温和的反应条件下以一体化方式制造4,4'-双吡啶化合物，无需中间体的分离。